In a study using mice, the researchers found long-term damage in the lungs—even after the virus had gone and symptoms had ...

Following the first Phase 3 study of HyBryte(TM) for the treatment of CTCL, the FDA and the EMA indicated that they would require a second successful Phase 3 trial to support mark ...

Patients recovering from respiratory sepsis vs COVID- or pneumonia-related sepsis face the highest burden of postacute impairments and mortality.

Invivyd surged after Merck’s Cidara acquisition, but the read-through for IVVD is limited due to key differences. Learn why ...

Diagne, G. , Konate, S. , Mbaye, A. , Kane, A. , Sow, N. , Cisse, D. , Ly, F. and Ndiaye, O. (2025) Acute Respiratory ...

The Authority is the world's first real-time retailer integration, encapsulation, grading, buy/sell marketplace, and fulfillment all on a single platform. The Authority is the first trusted, vaulted ...

RNA vaccine technology has emerged as a groundbreaking approach in the field of immunology and infectious disease prevention.

Gad, O.S. and Marshood, A. (2025) Bilateral Autoimmune Multifocal Choroiditis Following COVID-19 Vaccination. Open Journal of ...

Invivyd intends to use the net proceeds that it will receive from the offering, together with its existing cash and cash equivalents, for commercial preparedness for the potential launch of VYD2311, ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today ...

The securities described above are being offered by Invivyd pursuant to a shelf registration statement on Form S-3 (File No. 333-267643) filed with the U.S. Securities and Exchange Commission (SEC) on ...

A new study led by University of Toronto researchers has shown that immune cells in the gut follow an atypical pathway to ...